Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 in Recurrent or Metastatic Cervical Cancer
NCT04868708Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Apr 2021
- Primary completion
- Feb 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in Cervical Cancer (CC), sponsored by Akeso, Inc.. Started Apr 2021; status: completed.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04868708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04868708.